KiOmed Pharma receives approval from the Chinese FDA for KioMedineVSone
KiOmed Pharma announces that the National Medical Products Administration (NMPA) of China has approved KioMedinevsone, its innovative treatment for osteoarthritis.
With this approval, KiOmed Pharma is now authorized to commercialize its product in mainland China,Macau, Hong Kong and Taiwan, with a launch planned for early 2026 in partnership with Hansoh, one of China’s leading biopharmaceutical companies.
“This approval goes far beyond a regulatory milestone; it marks a turning point in our company’s history,” said François Blondel, Founder and Executive Chairman of KiOmed Pharma. “We are not only entering one of the world’s largest healthcare markets, but we are also bringing a truly innovative solution to more than 100 million people in China suffering from osteoarthritis.”
Osteoarthritis represents a major public health challenge in China, both due to the large number of patients affected and the economic burden it places on the healthcare system, particularly as sustainable treatment options remain limited.
“This milestone confirms the position of our Belgian innovation at the forefront of a major medical and economic issue,” added Houtaï Choumane, CEO of KiOmed Pharma. “It paves the way for unprecedented growth and impact. We are proud of the work done by our teams, grateful to our partner Hansoh, and excited to success fully launch this product together.”
About KiOmed Pharma
Founded in 2014, KiOmed Pharma is a Belgian company specialised in the development of injectable medical devices based on a highly purified chitosan derivative of non-animal origin. A subsidiary of KitoZyme, the company focuses on three therapeutic areas: rheumatology, aesthetic medicine and ophthalmology, with the aim of addressing unmet clinical needs through safe and targeted medical solutions.
About KioMedinevsone
KioMedinevsone, the company’s first product, currently commercialized in 15 countries, is a unique fluid implant indicated for the symptomatic treatment of knee osteoarthritis via a single intraarticular injection, providing up to 12 months symptom relief. KioMedinevsone is targeted to refractory knee OA patients, who do not respond well to existing treatments and constitutes for these patients a cost-effective alternative to TKR surgery, that can potentially be delayed or avoided.
Read more : www.kiomedine-one.com
Contact
- [email protected]
- +32 4 228 80 40